Progesterone receptor modulates ERα action in breast cancer
Hisham Mohammed, I Alasdair Russell, Rory Stark, Oscar M Rueda, Theresa E Hickey, Gerard A Tarulli, Aurelien A Serandour, Stephen N Birrell, Alejandra Bruna, Amel Saadi, Suraj Menon, James Hadfield, Michelle Pugh, Ganesh V Raj, Gordon D Brown, Clive D'Santos, Jessica L L Robinson, Grace Silva, Rosalind Launchbury, Charles M Perou, John Stingl, Carlos Caldas, Wayne D Tilley, Jason S Carroll, Hisham Mohammed, I Alasdair Russell, Rory Stark, Oscar M Rueda, Theresa E Hickey, Gerard A Tarulli, Aurelien A Serandour, Stephen N Birrell, Alejandra Bruna, Amel Saadi, Suraj Menon, James Hadfield, Michelle Pugh, Ganesh V Raj, Gordon D Brown, Clive D'Santos, Jessica L L Robinson, Grace Silva, Rosalind Launchbury, Charles M Perou, John Stingl, Carlos Caldas, Wayne D Tilley, Jason S Carroll
Abstract
Progesterone receptor (PR) expression is used as a biomarker of oestrogen receptor-α (ERα) function and breast cancer prognosis. Here we show that PR is not merely an ERα-induced gene target, but is also an ERα-associated protein that modulates its behaviour. In the presence of agonist ligands, PR associates with ERα to direct ERα chromatin binding events within breast cancer cells, resulting in a unique gene expression programme that is associated with good clinical outcome. Progesterone inhibited oestrogen-mediated growth of ERα(+) cell line xenografts and primary ERα(+) breast tumour explants, and had increased anti-proliferative effects when coupled with an ERα antagonist. Copy number loss of PGR, the gene coding for PR, is a common feature in ERα(+) breast cancers, explaining lower PR levels in a subset of cases. Our findings indicate that PR functions as a molecular rheostat to control ERα chromatin binding and transcriptional activity, which has important implications for prognosis and therapeutic interventions.
Figures
References
- Chlebowski RT, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304:1684–1692. doi:10.1001/jama.2010.1500 304/15/1684 [pii]
- Bentel JM, et al. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol. 1999;154:11–20. doi:S0303-7207(99)00109-4 [pii]
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast cancer research and treatment. 2008;107:103–111. doi:10.1007/s10549-007-9523-x.
- Blows FM, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279. doi:10.1371/journal.pmed.1000279.
- Vignon F, Bardon S, Chalbos D, Rochefort H. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. J Clin Endocrinol Metab. 1983;56:1124–1130.
- Musgrove EA, Swarbrick A, Lee CS, Cornish AL, Sutherland RL. Mechanisms of cyclin-dependent kinase inactivation by progestins. Molecular and cellular biology. 1998;18:1812–1825.
- Chen CC, Hardy DB, Mendelson CR. Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1) The Journal of biological chemistry. 2011;286:43091–43102. doi:10.1074/jbc.M111.295865 M111.295865 [pii]
- Kabos P, et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast cancer research and treatment. 2012;135:415–432. doi:10.1007/s10549-012-2164-8.
- Zheng ZY, Bay BH, Aw SE, Lin VC. A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells. The Journal of biological chemistry. 2005;280:17480–17487. doi:M501261200 [pii] 10.1074/jbc.M501261200.
- Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973–1979. doi:10.1200/JCO.2003.09.099 JCO.2003.09.099 [pii]
- Pichon MF, Pallud C, Brunet M, Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer research. 1980;40:3357–3360.
- Badwe R, et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J Clin Oncol. 2011;29:2845–2851. doi:10.1200/JCO.2010.33.0738 JCO.2010.33.0738 [pii]
- Bines J, et al. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. Ann Oncol. 2014 doi:mdu015 [pii] 10.1093/annonc/mdu015.
- Lee YJ, Gorski J. Estrogen-induced transcription of the progesterone receptor gene does not parallel estrogen receptor occupancy. Proc Natl Acad Sci U S A. 1996;93:15180–15184.
- Dowsett M, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005;23:7512–7517. doi:23/30/7512 [pii] 10.1200/JCO.2005.01.4829.
- Thurlimann B, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The New England journal of medicine. 2005;353:2747–2757. doi:353/26/2747 [pii] 10.1056/NEJMoa052258.
- Viale G, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25:3846–3852. doi:JCO.2007.11.9453 [pii] 10.1200/JCO.2007.11.9453.
- Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721–7735. doi:23/30/7721 [pii] 10.1200/JCO.2005.09.004.
- Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature genetics. 2011;43:27–33. doi:ng.730 [pii] 10.1038/ng.730.
- Read LD, Snider CE, Miller JS, Greene GL, Katzenellenbogen BS. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Molecular endocrinology . 1988;2:263–271. (Baltimore, Md)
- Mohammed H, et al. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep. 2013;3:342–349. doi:10.1016/j.celrep.2013.01.010 S2211-1247(13)00017-X [pii]
- Ballare C, et al. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Molecular and cellular biology. 2003;23:1994–2008.
- Heintzman ND, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature. 2009;459:108–112. doi:nature07829 [pii] 10.1038/nature07829.
- Stark R, Brown GD. DiffBind: differential binding analysis of ChIP-Seq peak data. Bioconductor. .
- Clarke CL, Graham JD. Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS ONE. 2012;7:e35859. doi:10.1371/journal.pone.0035859 PONE-D-12-00543 [pii]
- Liang Y, Besch-Williford C, Brekken RA, Hyder SM. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer research. 2007;67:9929–9936. doi:67/20/9929 [pii] 10.1158/0008-5472.CAN-07-1103.
- Centenera MM, et al. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res. 2012;18:3562–3570. doi:10.1158/1078-0432.CCR-12-0782 1078-0432.CCR-12-0782 [pii]
- Dean JL, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012;11:2756–2761. doi:10.4161/cc.21195 21195 [pii]
- Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–352. doi:10.1038/nature10983 nature10983 [pii]
- Tomlinson IP, Nicolai H, Solomon E, Bodmer WF. The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J Pathol. 1996;180:38–43. doi:10.1002/(SICI)1096-9896(199609)180:1<38::AID-PATH638>;2-C [pii] 10.1002/(SICI)1096-9896(199609)180:1<38::AID-PATH638>;2-C.
- Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404. doi:10.1158/-12-0095 2/5/401 [pii]
- Schmidt D, et al. ChIP-seq: Using high-throughput sequencing to discover protein-DNA interactions. Methods. 2009 doi:S1046-2023(09)00047-4 [pii] 10.1016/j.ymeth.2009.03.001.
- Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25:1105–1111. doi:10.1093/bioinformatics/btp120 btp120 [pii] (Oxford, England)
- Anders S, Huber W. Differential expression analysis for sequence count data. Genome biology. 2010;11:R106. doi:10.1186/gb-2010-11-10-r106 gb-2010-11-10-r106 [pii]
- Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–15550. doi:0506580102 [pii] 10.1073/pnas.0506580102.
- Tilley WD, et al. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer research. 1994;54:4096–4102.
- Bengtsson H, Wirapati P, Speed TP. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics. 2009;25:2149–2156. doi:10.1093/bioinformatics/btp371 btp371 [pii] (Oxford, England)
- Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 2007;23:657–663. doi:btl646 [pii] 10.1093/bioinformatics/btl646. (Oxford, England)
- Dunning MJ, Smith ML, Ritchie ME, Tavare S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics. 2007;23:2183–2184. (Oxford, England)
- Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG. BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics. 2008;24:2921–2922. doi:btn557 [pii] 10.1093/bioinformatics/btn557. (Oxford, England)
- Barbosa-Morais NL, et al. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res. 2010;38:e17. doi:10.1093/nar/gkp942 gkp942 [pii]
- Parker JS, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–1167. doi:10.1200/JCO.2008.18.1370 JCO.2008.18.1370 [pii]
Source: PubMed